PLYMOUTH MEETING, Pa., Jan. 8 /PRNewswire-FirstCall/ -- Genaera Corporation will present at the 22nd Annual JP Morgan Healthcare Conference on Thursday, January 15, 2004 at 10:00AM (ET). The conference is being held at the Westin St. Francis Hotel in San Francisco.
Roy C. Levitt, President and Chief Executive Officer, will present highlights related to the Company’s three development programs, including squalamine, IL9 antibody and the mucoregulator program, including LOMUCIN(TM). Dr. Levitt will also review upcoming investment and product development milestones.
“We are delighted to have been invited to present at the JP Morgan Conference. This is an excellent opportunity to increase Genaera’s visibility and share our future with the investment community,” Dr. Levitt commented.
Genaera’s presentation will be webcast live which investors may access via the Internet at: http://equityconferences.jpmorgan.com/.
Genaera Corporation is a biopharmaceutical company committed to developing medicines for serious diseases from genomics and natural products. Research and development efforts are focused on anti-angiogenesis and respiratory diseases. Genaera has three products in development addressing substantial unmet medical needs in major pharmaceutical markets. These include squalamine, an anti-angiogenesis treatment for cancer and eye disease; interleukin-9 antibody, a respiratory treatment based on the discovery of a genetic cause of asthma; and LOMUCIN(TM), a mucoregulator to treat the overproduction of mucus and secretions involved in many forms of chronic respiratory disease.
This announcement contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties, known and unknown. Forward-looking statements reflect management’s current views and are based on certain expectations and assumptions. Such statements include, among others, statements regarding the preliminary results and future clinical development plans and prospects for squalamine (for lung cancer, prostate cancer and in other indications), the IL-9 antibody program and the small molecule mucoregulator program. You may identify some of these forward looking-statements by the use of words in the statements such as “anticipate,” “develop,” “continuing,” and “progress,” or other words of similar meaning. Genaera’s actual results and performance could differ materially from those currently anticipated and expressed in these and other forward-looking statements as a result of a number of risk factors, including, but not limited to, Genaera’s history of operating losses since inception and its need for additional funds to operate its business; the costs, delays and uncertainties inherent in scientific research, drug development, clinical trials and the regulatory approval process; the risk that clinical trials for Genaera’s product candidates, including squalamine and LOMUCIN(TM), may not be successful; the risk that Genaera may not obtain regulatory approval for its products, whether due to adequacy of the development program, the conduct of the clinical trials, changing regulatory requirements, different methods of evaluating and interpreting data, regulatory interpretations of clinical risk and benefit, or otherwise; Genaera’s reliance on its collaborators, including MedImmune, in connection with the development and commercialization of Genaera’s product candidates; market acceptance of Genaera’s products, if regulatory approval is achieved; competition; general financial, economic, regulatory and political conditions affecting the biotechnology industry; and the other risks and uncertainties discussed in this announcement and in Genaera’s filings with the U.S. Securities and Exchange Commission, all of which are available from the Commission in its EDGAR database at http://www.sec.gov/ as well as other sources. You are encouraged to read these reports. Given the uncertainties affecting pharmaceutical companies in the development stage, you are cautioned not to place undue reliance on any such forward-looking statements, any of which may turn out to be wrong due to inaccurate assumptions, unknown risks, uncertainties or other factors. Genaera does not intend (and it is not obligated) to publicly update, revise or correct these forward-looking statements or the risk factors that may relate thereto.
Genaera Corporation
CONTACT: Jennifer Bilotti of Genaera Corporation, +1-610-941-4020;Investor Inquiries: Jonathan Fassberg +1-212-477-9007 ext. 16, or MediaInquiries: Brad Miles +1-212-477-9007 ext. 17, both of The Trout Group/BMCCommunications
Web site: http://www.genaera.com/
